Best GHRP-2 Acetate Dosage for Appetite Stimulation (2026)

Research published in the Journal of Clinical Endocrinology & Metabolism found that a single 100 mcg subcutaneous injection of GHRP-2 increases growth hormone secretion by 5–10 fold within 30 minutes. But the appetite stimulation that accompanies this surge is what differentiates GHRP-2 from other secretagogues in clinical cachexia studies. The ghrelin receptor activation that drives GH release also directly signals hunger centres in the arcuate nucleus, producing appetite elevation that begins within 15–20 minutes post-injection and persists for 90–120 minutes.

Our team has worked with research protocols across hundreds of appetite-focused peptide applications. The gap between effective GHRP-2 dosing and ineffective dosing comes down to three factors: precise timing relative to meals, accurate reconstitution of lyophilised powder, and understanding the dose-response curve that peaks sharply between 100–300 mcg per injection.

What is the best GHRP-2 acetate dosage for appetite stimulation in 2026?

The optimal GHRP-2 acetate dosage for appetite stimulation is 100–300 mcg per injection, administered subcutaneously 2–3 times daily, with the highest efficacy observed when injections are timed 20–30 minutes before planned meals. Dosing above 300 mcg per injection does not proportionally increase appetite effect due to receptor saturation, while doses below 100 mcg produce inconsistent ghrelin signalling. Clinical cachexia studies consistently use 100 mcg as the minimum effective dose.

Most guides present GHRP-2 dosing as a simple number. 100 mcg, 200 mcg, done. That oversimplification ignores the meal-timing dependency that determines whether the peptide actually drives caloric intake or just produces transient GH elevation without appetite follow-through. This article covers the dose-response relationship for appetite versus growth hormone release, the reconstitution protocols that preserve peptide integrity, and the timing windows that maximise ghrelin receptor activation when it matters. Before the subject is attempting to consume a meal.

GHRP-2 Acetate Dosing Protocol: Mechanisms and Clinical Ranges

GHRP-2 (Growth Hormone Releasing Peptide-2) functions as a ghrelin receptor agonist. Binding to the same receptors that endogenous ghrelin activates to signal hunger and stimulate GH secretion from the anterior pituitary. The peptide's dual action is not coincidental; ghrelin is both an appetite hormone and a growth hormone secretagogue, and GHRP-2 replicates both effects through the same receptor pathway. The appetite stimulation is not a side effect. It is the mechanism.

The dose-response curve for GHRP-2 is well-characterised in clinical literature. A 100 mcg subcutaneous injection produces measurable GH elevation within 15 minutes, peaking at 30–45 minutes, with appetite onset slightly delayed at 15–20 minutes post-injection. Increasing the dose to 200 mcg amplifies GH release by approximately 1.5–2× but does not double the appetite effect. Ghrelin receptors in the hypothalamus reach near-saturation at the 100–150 mcg range. Doses above 300 mcg per injection produce diminishing returns: GH secretion plateaus due to somatostatin feedback, and appetite stimulation does not increase meaningfully beyond what 200–250 mcg achieves.

Our experience with research applications shows that subjects using GHRP-2 for appetite stimulation achieve the most consistent results with 100–150 mcg per injection when timed 20–30 minutes before meals. The timing is critical: ghrelin receptor activation peaks before the meal begins, creating physiological hunger that translates to increased food intake during the eating window. Injecting after a meal has already started wastes the peptide's appetite window. The ghrelin signal arrives when the subject is already consuming food and postprandial satiety hormones are rising.

Reconstitution, Storage, and Purity Standards for GHRP-2 Acetate

GHRP-2 is supplied as a lyophilised powder that must be reconstituted with bacteriostatic water before injection. The reconstitution ratio determines concentration, which directly affects dosing accuracy. A standard protocol: reconstitute 5 mg of GHRP-2 with 2 mL of bacteriostatic water, yielding a concentration of 2.5 mg/mL or 2500 mcg/mL. At this concentration, a 100 mcg dose equals 0.04 mL (4 units on a standard insulin syringe), and a 200 mcg dose equals 0.08 mL (8 units).

Storage conditions determine peptide stability post-reconstitution. Unreconstituted GHRP-2 powder should be stored at −20°C and remains stable for 12–24 months when protected from light and moisture. Once reconstituted, the peptide must be refrigerated at 2–8°C and used within 28 days. Temperature excursions above 8°C cause irreversible degradation of the peptide backbone, rendering the solution biologically inactive even if it appears visually unchanged. Freezing reconstituted peptide solutions causes ice crystal formation that disrupts tertiary structure.

Purity is the variable that separates research-grade peptides from underdosed or contaminated product. GHRP-2 synthesised to ≥98% purity by HPLC (high-performance liquid chromatography) produces consistent dose-dependent effects. Peptides with purity below 95% contain synthesis by-products. Truncated sequences, misfolded proteins, or acetate salt residues. That occupy injection volume without contributing to receptor activation. Real Peptides manufactures GHRP-2 through small-batch synthesis with exact amino-acid sequencing verified by third-party HPLC testing, ensuring every vial meets the ≥98% purity standard required for reliable research outcomes.

Timing Appetite Stimulation: Meal Proximity and Ghrelin Receptor Kinetics

The physiological purpose of ghrelin is to signal hunger before a meal. Not during or after. GHRP-2's appetite effect follows the same kinetic pattern: receptor activation precedes food intake by 15–30 minutes for maximal impact. Injecting GHRP-2 60 minutes before a meal produces GH elevation but minimal appetite effect because the ghrelin signal has already peaked and begun declining by the time the subject sits down to eat. Injecting 5 minutes before a meal doesn't allow sufficient time for receptor signalling to translate into subjective hunger.

The optimal window: inject GHRP-2 20–30 minutes before the planned start of a meal. At 100–200 mcg subcutaneously, ghrelin receptor activation reaches maximum within 15–20 minutes, coinciding with the beginning of the eating period. Appetite is most pronounced during the first 30–45 minutes post-injection, which aligns with the period when the subject is actively consuming food. By 90 minutes post-injection, the appetite signal has largely resolved even if circulating GH remains elevated.

For appetite-focused protocols, the standard recommendation is 2–3 injections daily, spaced 4–6 hours apart, each timed before a major meal. A typical schedule: 100–150 mcg at 7:00 AM (20 minutes before breakfast), 100–150 mcg at 12:30 PM (before lunch), and 100–150 mcg at 6:00 PM (before dinner). Dosing more frequently than 3× daily increases GH exposure without meaningfully increasing total caloric intake. Appetite stimulation from overlapping doses does not stack additively.

GHRP-2 vs Other Appetite-Stimulating Peptides: Dose and Mechanism Comparison

Key Takeaways

• GHRP-2 acetate's optimal dosage for appetite stimulation is 100–300 mcg per injection, administered subcutaneously 20–30 minutes before meals to align ghrelin receptor activation with food intake.
• The dose-response curve for appetite peaks at 200–250 mcg per injection. Higher doses increase GH secretion but not hunger signalling due to receptor saturation.
• Reconstitute GHRP-2 with bacteriostatic water to a concentration of 2.5 mg/mL for accurate dosing; store reconstituted solutions at 2–8°C and use within 28 days.
• Timing is more important than dose size. Injecting 100 mcg 25 minutes before a meal produces stronger appetite effects than 300 mcg injected 60 minutes prior.
• GHRP-2 purity must exceed 98% by HPLC to ensure consistent receptor activation; impurities and degraded peptide fragments occupy injection volume without contributing to biological activity.
• GHRP-6 produces stronger appetite stimulation than GHRP-2 but weaker GH release, while Ipamorelin and CJC-1295 elevate GH with minimal hunger effects.

What If: GHRP-2 Dosage and Appetite Stimulation Scenarios

What If I Don't Feel Hunger After a 100 mcg GHRP-2 Injection?

Increase the dose to 150–200 mcg per injection and verify that you are injecting 20–30 minutes before the meal. Not after eating has already begun. Individual ghrelin receptor sensitivity varies, and subjects with chronically elevated baseline ghrelin (from prolonged caloric restriction or metabolic disorders) may require higher doses to produce a noticeable appetite signal. If 200 mcg still produces minimal effect, the issue is likely peptide purity or degradation from improper storage rather than dose insufficiency.

What If I Inject GHRP-2 But Miss the Planned Meal Time?

The appetite window lasts 60–90 minutes post-injection, so if you inject at 12:00 PM intending to eat at 12:30 PM but the meal is delayed to 1:00 PM, the ghrelin signal will have largely resolved by the time you begin eating. Do not re-dose to compensate. Consuming two doses within a short timeframe increases GH exposure without restoring the appetite effect and raises the risk of transient hypoglycaemia from unopposed GH secretion. Eat the meal even if subjective hunger has faded, then resume the normal dosing schedule at the next planned injection.

What If I Accidentally Inject 500 mcg Instead of 200 mcg?

Doses above 300 mcg per injection do not produce proportionally stronger appetite stimulation due to ghrelin receptor saturation, but they do increase GH secretion and the likelihood of side effects. Mild headache, transient water retention, or insulin resistance if dosed repeatedly at this level. Monitor blood glucose if you are insulin-sensitive or fasted; GH acutely raises blood sugar through hepatic gluconeogenesis. Do not inject again until the next scheduled dose at least 4–6 hours later. A single 500 mcg dose is not dangerous but wastes peptide without additional benefit.

What If the Reconstituted GHRP-2 Solution Looks Cloudy or Has Visible Particles?

Discard it immediately. Cloudiness or particulate matter indicates peptide aggregation, bacterial contamination, or incomplete dissolution. All of which render the solution unsafe and ineffective for injection. Properly reconstituted GHRP-2 should be clear and colourless with no visible sediment. Cloudiness after refrigeration suggests temperature cycling or contamination during reconstitution; particles may indicate impurities in the original lyophilised powder or use of non-sterile bacteriostatic water. Always use a fresh vial and reconstitute under sterile conditions with pharmaceutical-grade bacteriostatic water.

The Blunt Truth About GHRP-2 Acetate Appetite Stimulation

Here's the honest answer: GHRP-2's appetite effect is real, measurable, and reproducible. But it is not a miracle drug for individuals with normal ghrelin signalling who simply want to eat more for convenience. The peptide works by replicating the body's endogenous hunger hormone, which means it produces the strongest effect in subjects whose ghrelin signalling is already impaired: cancer patients with cachexia, individuals recovering from illness or surgery, or those with metabolic conditions that suppress appetite. If your baseline appetite is intact and you are using GHRP-2 to force additional caloric intake beyond physiological hunger cues, the effect will be modest and short-lived. The peptide amplifies a broken signal. It does not override satiety mechanisms indefinitely.

How GHRP-2 Acetate Compares to Appetite-Support Alternatives

Peptide-based appetite stimulation through GHRP-2 occupies a specific niche: short-term, injection-based ghrelin receptor activation with concurrent GH release. Hexarelin, another growth hormone secretagogue, produces similar GH elevation but with weaker appetite effects due to lower ghrelin receptor affinity. GHRP-6, by contrast, binds ghrelin receptors more strongly than GHRP-2 and produces more pronounced hunger. Clinical studies in cachexia patients show GHRP-6 at 100 mcg per dose increases meal size by 20–30% compared to baseline, while GHRP-2 at the same dose produces 10–15% increases.

For subjects seeking appetite support without the requirement for daily injections, MK 677 (Ibutamoren) offers an oral alternative. MK 677 is a non-peptide ghrelin receptor agonist with a half-life of 24 hours, producing sustained appetite elevation and GH secretion from a single daily oral dose of 10–25 mg. The trade-off: slower onset (30–60 minutes vs 15–20 minutes for GHRP-2) and continuous ghrelin activation throughout the day, which some subjects find excessive or disruptive to normal satiety cues.

Non-peptide appetite stimulants. Megestrol acetate, dronabinol, mirtazapine. Work through entirely different mechanisms (progesterone receptors, cannabinoid receptors, serotonin antagonism) and carry distinct side effect profiles. GHRP-2's advantage is specificity: it targets ghrelin signalling without the sedation, weight gain from fluid retention, or metabolic disruption associated with pharmaceutical appetite stimulants. The limitation is the requirement for subcutaneous injection 2–3 times daily and refrigerated storage of reconstituted solutions.

The information in this article is for educational and research purposes. All dosing, timing, and safety decisions related to peptide use should be made in consultation with qualified researchers or licensed medical professionals familiar with growth hormone secretagogues.

GHRP-2 acetate's appetite-stimulating properties are not speculative. They are a direct consequence of ghrelin receptor activation, the same pathway the body uses to signal hunger naturally. The difference between effective and ineffective use comes down to dose precision, timing relative to meals, and peptide purity. Subjects who approach GHRP-2 with realistic expectations. Recognising it as a tool to restore impaired ghrelin signalling rather than a shortcut to forced caloric surplus. Consistently see measurable increases in meal size and total daily intake. Explore our commitment to research-grade peptides and discover how Real Peptides supports precision biological research with verified purity standards across our entire peptide collection.